Companies / Arbutus Biopharma Corp

Arbutus Biopharma Corp

Nasdaq: ABUSCIK 1447028WARMINSTER, PAarbutusbio.com ↗

Financials · FY2025

Revenue$14.08M
Net income$-33.50M
Total debt$0
Cash$19.17M
Diluted EPS$-0.17
Shares outstanding197.8M

Ownership

197.8M shares outstanding · as of Aug 10, 2026
0.05%Insiders
Ownership
Insiders0.05%101,500
Institutions62.45%123,552,852
Public float37.50%74,193,483

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 3

View all →
Insider% of sharesShares
Nguyen TuanChief Financial Officer
0.04%73,500
Androski LindsayCEOPresident and CEO · Director
0.01%28,000
Beardsley Robert ADirector
——

Institutional holders 178

View all →
HolderValue% of shares
Morgan Stanley$128.44M13.50%
BlackRock, Inc.$66.08M6.96%
Whitefort Capital Management, LP$64.18M6.74%
Two Seas Capital LP$60.55M6.36%
Vanguard Group Inc$44.46M4.67%
State Street Corporation$37.77M3.98%
ADAR1 Capital Management, LLC$26.05M2.74%
Geode Capital Management, LLC$16.98M1.91%
Adage Capital Partners Gp, L.L.C.$11.99M1.35%
Woodline Partners LP$10.52M1.11%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Feb 2, 2026Nguyen Tuan
Executive
GrantCommon Shares$0+74K
73,500
0.04% of shares
low
Feb 2, 2026Androski Lindsay
CEO
GrantCommon Shares$0+28K
28,000
0.01% of shares
low
Jun 8, 2026Beardsley Robert A
Director
GrantStock Option (Right to Buy)—+79K
78,800
0.04% of shares
low
Feb 2, 2026Nguyen Tuan
Executive
GrantStock Option (Right to Buy)—+188K
188,400
0.10% of shares
low
Feb 2, 2026Androski Lindsay
CEO
GrantStock Option (Right to Buy)—+72K
71,700
0.04% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Morgan StanleyPassive13G/A———
Two Seas Capital LPPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
ABUSCommon StockEquity03879J100BBG000RR8V85